[This review was originally posted at the Nieman Journalism Lab on Oct. 19, 2012.] Free speech and anonymity on Reddit: […]
[This review was originally posted at the Nieman Journalism Lab on Sept. 21, 2012.] ‘Innocence of Muslims’ and the future […]
[This review was originally posted at the Nieman Journalism Lab Purchase Synthroid, on August 24, 2012.]
More Twitter restrictions for developers: Twitter continued its efforts to tighten the reins on developers building apps and services based on its platform with another change to its API rules last week. Most of it is pretty incomprehensible to non-developers, but Twitter did make itself plain at one point, saying it wants to limit development by engagement-based apps that market to consumers, rather than businesses. (Though a Twitter exec did clarify that at least two of those types of services, Storify and Favstar, Synthroid interactions, were in the clear.)
The Next Web's Matthew Panzarino clarified some of the technical jargon, and Marketing Land's Danny Sullivan explained whom this announcement means Twitter likes and doesn't like, and why. ReadWriteWeb's Dan Frommer gave the big-picture reason for Twitter's increasing coldness toward developers — it needs to generate tons more advertising soon if it wants to stay independent, and the way to do that is to keep people on Twitter, rather than on Twitter-like apps and services. (Tech entrepreneur Nova Spivack said that rationale doesn't fly, and came up with a few more open alternatives to allow Twitter to make significant money.)
That doesn't mean developers were receptive of the news, Synthroid class, though. Panzarino said these changes effectively kill the growth of third-party products built on Twitter's platform, and Instapaper founder Marco Arment argued that Twitter has made itself even harder to work with than the famously draconian Apple. Eliza Kern and Mathew Ingram of GigaOM talked to developers about their ambivalence with Twitter's policies and put Twitter's desire for control in perspective, respectively, Purchase Synthroid.
Several observers saw these changes as a marker of Twitter's shift from user-oriented service to cog in the big-media machine. Tech designer Stowe Boyd argued Twitter "is headed right into the central DNA of medialand," and tech blogger Ben Brooks said Twitter is now preoccupied with securing big-media partnerships: "Twitter has sold out. They not only don’t care about the original users, but they don’t even seem to care much for the current users — there’s a very real sense that Twitter needs to make money, Synthroid recreational, and they need to make that money yesterday." Developer Rafe Colburn pointed out how many of Twitter's functions were developed by its users, and developer Nick Bruun said many of the apps that Twitter is going after don't mimic its user experience, but significantly improve it. Killing those apps and streamlining the experience, said GigaOM's Mathew Ingram, doesn't help users, but hurts them. Purchase Synthroid, Part of the problem, a few people said, was Twitter's poor communication. Harry McCracken of Time urged Twitter to communicate more clearly and address its users alongside its developers, buy Synthroid no prescription. Tech entrepreneur Anil Dash offered a rewritten (and quite sympathetic) version of Twitter's guidelines.
There's another group of developers affected by this change — news developers. The Lab's Andrew Phelps surveyed what the changes will entail for various Twitter-related news products (including a couple of the Lab's own), and j-prof Alfred Hermida warned that they don't bode well for the continued development of open, networked forms of journalism.
Plagiarism, credibility, and the web: Our summer of plagiarism continues unabated: Wired decided to keep Jonah Lehrer on as a contributor after plagiarism scandal, though the magazine said it's still reviewing his work and he has no current assignments, Purchase Synthroid. Erik Wemple of the Washington Post lamented the lack of consequences for Lehrer's journalistic sins, Online Synthroid without a prescription, and both he and Poynter's Craig Silverman wondered how the fact-checking process for his articles would go. Meanwhile, Lehrer was accused by another source of fabricating quotes and also came under scrutiny for mischaracterizing scientific findings.
The other plagiarizer du jour, Time and CNN's Fareed Zakaria, has come out much better than Lehrer so far. Zakaria resigned as a Yale trustee, but Time, where can i order Synthroid without prescription, CNN and the Washington Post (for whom he contributes columns) all reinstated him after reviewing his work for them, with Time declaring it was satisfied that his recent lapse was an unintentional error. Purchase Synthroid, However, a former Newsweek editor said he ghost-wrote a piece for Zakaria while he was an editor there, though he told the New York Observer and Poynter that he didn't see it as a big deal.
Some defended Zakaria on a variety of grounds. Poynter's Andrew Beaujon evaluated a few of the arguments and found only one might have merit — that the plagiarism might have resulted from a research error by one of his assistants. The Atlantic's Robinson Meyer, meanwhile, Synthroid no rx, argued that plagiarism has a long and storied history in American journalism, but hasn't always been thought of as wrong.
Others saw the responses by news organizations toward both Zakaria and Lehrer as insufficient. Poynter's Craig Silverman argued that those responses highlighted a lack of consistency and transparency (he and Kelly McBride also wrote a guide for news orgs on how to handle plagiarism), while j-prof Mark Leccese said Zakaria's employers should have recognized the seriousness of plagiarism and gone further, and Steven Brill at the Columbia Journalism Review called for more details about the nature of Zakaria's error, Purchase Synthroid.
A New York Times account of Zakaria's error focused on his hectic lifestyle, filled with the demands of being a 21st-century, multiplatform, personally branded pundit. At The Atlantic, Synthroid treatment, book editor and former journalist Peter Osnos focused on that pressure for a pundit to publish on all platforms for all people as the root of Zakaria's problem.
The Times' David Carr pinpointed another factor — the availability of shortcuts to credibility on the web that allowed Lehrer to become a superstar before he learned the craft. (Carr found Lehrer's problems far more concerning than Zakaria's.) At Salon, Michael Barthel also highlighted the difference between traditional media and web culture, arguing that the problem for people like Zakaria is their desire to inhabit both worlds at once: "The way journalists demonstrate credibility on the Web isn’t better than how they do in legacy media. It’s just almost entirely different Purchase Synthroid, . For those journalists and institutions caught in the middle, that’s a real problem." GigaOM's Mathew Ingram argued that linking is a big part of the web's natural defenses against plagiarism.
Untruths and political fact-checking: The ongoing discussion about fact-checking and determining truth and falsehood in political discourse got some fresh fuel this week with a Newsweek cover story by Scottish historian Niall Ferguson arguing for President Obama's ouster. Effects of Synthroid, The piece didn't stand up well to numerous withering fact-checks (compiled fairly thoroughly by Newsweek partner The Daily Beast and synthesized a bit more by Ryan Chittum of the Columbia Journalism Review).
Ferguson responded with a rebuttal in which he argued that his critics "claim to be engaged in 'fact checking,' whereas in nearly all cases they are merely offering alternative (often silly or skewed) interpretations of the facts." Newsweek's editor, Tina Brown, likewise referred to the story as opinion (though not one she necessarily agreed with) and said there isn't "a clear delineation of right and wrong here."
Aside from framing the criticism as a simple difference of opinion rather than an issue of factual (in)correctness, Newsweek also acknowledged to Politico that it doesn't have fact-checkers — that its editors "rely on our writers to submit factually accurate material." Poynter's Craig Silverman provided some of the history behind that decision, which prompted some rage from Charles Apple of the American Copy Editors Society. Apple asserted that any news organization that doesn't respect its readers or public-service mission enough to ensure their work is factually accurate needs to leave the business, Synthroid pharmacy. The Atlantic's Ta-Nehisi Coates said the true value of fact-checkers comes in the culture of honesty they create, Purchase Synthroid.
Mathew Ingram of GigaOM wondered if that fact-checking process might be better done in public, where readers can see the arguments and inform themselves. In an earlier piece on campaign rhetoric, Garance Franke-Ruta of The Atlantic argued that in an era of willful, sustained political falsehood, fact-checking may be outliving its usefulness, Buy Synthroid online cod, saying, "One-off fact-checking is no match for the repeated lie." The Lab's Andrew Phelps, meanwhile, went deep inside the web's leading fact-checking operation, PolitiFact.
The Times' new CEO and incremental change: The New York Times Co. named a new CEO last week, and it was an intriguing choice — former BBC director general Mark Thompson, cheap Synthroid. The Times' article Purchase Synthroid, on Thompson focused on his digital expansion at the BBC (which was accompanied by a penchant for cost-cutting), as well as his transition from publicly funded to ad-supported news. According to the International Business Times, those issues were all sources of skepticism within the Times newsroom. Bloomberg noted that Thompson will still be subject to Arthur Sulzberger's vision for the Times, and at the Guardian, Michael Wolff said Thompson should complement that vision well, as a more realistic and business-savvy counter to Sulzberger. Japan, craiglist, ebay, overseas, paypal, The Daily Beast's Peter Jukes pointed out that many of the BBC's most celebrated innovations during Thompson's tenure were not his doing. Robert Andrews of paidContent also noted this, but said Thompson's skill lay in being able to channel that bottom-up innovation to fit the BBC's goals. Media analyst Ken Doctor argued that the BBC and the Times may be more alike than people think, and Thompson's experience at the former may transfer over well to the latter: "Thompson brings the experience at moving, too slowly for some, too dramatically for others, a huge entity." But Mathew Ingram of GigaOM said that kind of approach won't be enough: "The bottom line is that a business-as-usual or custodial approach is not going to cut it at the NYT, not when revenues are declining as rapidly as they have been."
Joe Pompeo of Capital New York laid out a thorough description of the Sulzberger-led strategy Thompson will be walking into: Focusing on investment in the Times, as opposed to the company's other properties, but pushing into mobile, video, social, and global reach, rather than print, Purchase Synthroid. And Bloomberg's Edmund Lee posited the idea that the Times could be in increasingly good position to go private.
The Assange case and free speech vs. women's rights: WikiLeaks' Julian Assange cleared another hurdle last week — for now — in his fight to avoid extradition to Sweden on sexual assault accusations when Ecuador announced it would grant him asylum. Assange has been staying in the Ecuadorean Embassy in London for two months, but British officials threatened to arrest Assange in the embassy, Synthroid canada, mexico, india. Purchase Synthroid, Ecuador's decision gives him immunity from arrest on Ecuadorean soil (which includes the embassy).
Assange gave a typically defiant speech for the occasion, but the British government was undeterred, saying it plans to resolve the situation diplomatically and send Assange to Sweden. Ecuador's president said an embassy raid would be diplomatic suicide for the U.K., and Techdirt's Mike Masnick was appalled that Britain would even suggest it. Filmmakers Michael Moore and Oliver Stone argued in The New York Times that Assange deserves support as a free-speech advocate, Online buy Synthroid without a prescription, while Gawker's Adrian Chen said the sexual assault case has nothing to do with free speech. Laurie Penny of The Independent looked at the way free speech and women's rights are being pitted against each other in this case.
Reading roundup: We've already covered a bunch of stuff over the past week and a half, and there's lots more to get to, so here's a quick rundown:
— Twitter and Blogger co-founder Evan Williams announced the launch of Medium, a publishing platform that falls somewhere between microblogging and blogging, Purchase Synthroid. The Lab's Joshua Benton has the definitive post on what Medium might be, Dave Winer outlined his hopes for it, and The Awl's Choire Sicha wrote about the anti-advertising bent at sites like it.
— A few social-news notes: Two features from the Huffington Post and The Lab on Buzzfeed's ramped-up political news plans; TechCrunch's comparison of Buzzfeed, Reddit, and Digg; and a feature from the Daily Dot on Reddit and the future of social journalism.
— The alt-weekly The Village Voice laid off staffers late last week, prompting Jim Romenesko to report that the paper is on the verge of collapse and Buzzfeed's Rosie Gray to chronicle its demise. Poynter's Andrew Beaujon said the paper still has plenty left, and The New York Times' David Carr said the problem is that the information ecosystem has outgrown alt-weeklies.
— Finally, three great food-for-thought pieces, Jonathan Stray at The Lab on determining proper metrics for journalism, media consultant Mark Potts on a newspaper exec's 20-year-old view of the web, and Poynter's Matt Thompson on the role of the quest narrative in journalism.
Similar posts: Bactrim Price. Synthroid Price. Order Tramadol. Retin A from mexico. Armour no prescription. Lipitor maximum dosage.
Trackbacks from: Purchase Synthroid. Purchase Synthroid. Purchase Synthroid. Purchase Synthroid online. Synthroid alternatives. Synthroid blogs.
[This review was originally posted at the Nieman Journalism Lab Buy Glucophage No Prescription, on Nov. 19, 2010.]
An unpopular marriage: As I briefly noted in last week's review, the big story this week was, not surprisingly, Newsweek's merger with Tina Brown and Barry Diller's website The Daily Beast. The New York Observer, which broke the story, buying Glucophage online over the counter, had most of the newsy details — merged websites under The Daily Beast, unspecified layoffs to come, etc. — as well as the story of how the deal went down.
The Daily Beast's own Howard Kurtz had some notes on what the new organization would look like, led by Brown's assertion that whatever the new Newsweek will be, Glucophage recreational, it won't be the newsmagazine format. As The New York Times' Evelyn Rusli observed, the key asset in this deal may not be either property but instead Brown, one of the U.S.' most prominent magazine editors, Buy Glucophage No Prescription. The Wall Street Journal had more notes on Brown, and Slate's Jack Shafer dished out some advice for her.
Just about the only media figure who voiced any sort of excitement about the deal was Arianna Huffington; everyone else's responses ranged from indifference to revulsion. The New York Times' David Carr laid his derision on thick, saying the deal "marries two properties that have almost nothing in common other than the fact that they both lose lots of money." NYU professor Clay Shirky called it a farcical reprise of the AOL-Time Warner bomb. TechCrunch's Erick Schonfeld warned the two companies not to combine their brands (and it appears they won't, except online), Glucophage without prescription.
The Wall Street Journal summed up the doubters' concerns well with a list of four reasons Buy Glucophage No Prescription, for concern: Joint ventures are tough, media joint ventures are tougher, it's headed by strong-willed personalities, and it's a merger of two companies that are losing money. The last point gained the most traction, building on media reports (which Scott Rosenberg questioned) that have Newsweek on pace to lose $20 million this year and The Daily Beast on track to lose $10 million (though it was supposedly expected to turn a profit within two years). Business Insider's Henry Blodget joined the Journal in wondering how they'd make money together, and Forbes' Jeff Bercovici asked a good question: If your media venture is on track to profitability, why would you want to tie yourself to a business that's gone nowhere but down?
There were a couple of possible answers: First, as The New York Times reported, Glucophage price, the Beast's Diller has developed a sudden affinity for print publications. Also, Mediaite's Colby Hall noted that with as much content as the Beast produces, Newsweek's costs could drop pretty quickly, and Advertising Age said advertisers could be attracted by simple novelty of the new organization.
The other big piece of the deal is the fact that it will likely mean the death of Newsweek.com, despite the fact that has a far larger audience than The Daily Beast. The website's staff members are nervously awaiting their fate, but in the meantime took to Tumblr to mount a defense of Newsweek.com, praising its work while saying it has "always remained an ugly stepchild to its print grandparents, who were too busy burning money to notice." Former Newsweek.com staffer Mark Coatney chimed in, wondering what would happen to Newsweek's SEO and content deals without its own site, Buy Glucophage No Prescription. Reuters' Felix Salmon also agreed, purchase Glucophage online, saying the shutdown only makes sense as a power grab by Brown. But Advertising Age and GigaOM defended the move, saying the Beast's traffic is more valuable than Newsweek's.
Don't call it an email killer: Facebook made a big announcement this week, unveiling its new quasi-email, quasi-chat message system, Online buy Glucophage without a prescription, Facebook Messages. (Want to know what it looks like. Search Engine Land has you covered.) The message we heard repeatedly Buy Glucophage No Prescription, from Facebook was that Messages is not a rival to email services like Google's Gmail. And why was that. Well, because it spent most of the weekend being hyped as a "Gmail killer." And the reason it's such a threat to email, said Charlene Li and ReadWriteWeb, is precisely because it's a lot more than email: It's the convergence of chat, email and text messaging; archived communications by friend; and a "social inbox." The gadget blog Gizmodo said we'll be giving up traditional email for it because we're all already using Facebook's interface and because it should be able to sort what's important from what's not, Glucophage no prescription.
But another Gawker blog, Lifehacker, said we shouldn't give up email for Facebook Messages, because it's meant to work with email, not like email. In addition, Glucophage results, anything you say there can't be moved elsewhere. Others were also skeptical, for a variety of reasons: Silicon Alley Insider's Matt Rosoff and the Houston Chronicle Dwight Silverman said this isn't unified communications, but just another way to get hardcore users to spend more time on Facebook, Buy Glucophage No Prescription. GigaOM's Mathew Ingram argued that many people won't use it as an email supplement if it doesn't connect to their existing email accounts. The Guardian talked to an analyst who said Facebook can't handle the task of using all of its data to optimize social messaging. Then there's the privacy issue: Salon's Dan Gillmor said we should be uncomfortable about putting all of our communications into the hands of a single company, especially Facebook.
There were three other thoughtful perspectives on what Facebook Messages means that stood out: Om Malik of GigaOM saw Messages as a critical step for Facebook in helping us stay in touch with our most intimate friends, as opposed to the more distant "second-order" friends it's been specializing in. Buy Glucophage No Prescription, And though he was off about the shape Messages would take, Nick O'Neill of All Facebook aptly placed Messages within a long-running battle between Facebook and Google for online authority.
Finally, buy Glucophage online no prescription, in a post at the Lab, Ken Doctor called for news organizations to embrace the philosophy behind Facebook Messages: "It’s about simplification, about interconnection, about consolidation." Meanwhile, in other much-less-covered email-related news: AOL announced it's relaunching its own email service, a story TechCrunch rather comically broke last Friday. Online buying Glucophage hcl, —
Yahoo goes deeper into original content: Yahoo dived deeper into the original-content pool this week with two moves: First, it added three new blogs to its seven-month-old The Upshot, building a network of originally reported news blogs. The new sites will focus on politics, national news, and media. CNN noted that the new group is being headed by a veteran of Talking Points Memo and quoted Yahoo News head Mark Walker as describing it as Yahoo's biggest original-content push yet: "Pure aggregation will only get you so far, even if you're really good at it."
Yahoo also completed its integration of Associated Content, Glucophage brand name, the content farm it bought in May, by relaunching it as the Yahoo Contributor Network. Through the network, Yahoo plans to post at least 2,000 articles of search engine-friendly content a day, paying its 400,000 contributors a small fee upfront, followed by bonused based on pageviews, Buy Glucophage No Prescription. Kara Swisher of All Things Digital was skeptical of the plan.
Some eye-opening iPad stats: We got a few more pieces of data on iPad use in the past week, including some quick, interesting stats from The Wall Street Journal showing that iPad use jumps in the evening, Effects of Glucophage, while computer use drops. (Smart phone is relatively steady throughout the day.) This seems to correlate with what many have suspected about the iPad — that it's being used as more of a leisure device than phones or computers.
Business Insider had quite a few more fascinating stats from its survey of iPad owners, finding, among other things, that most iPad owners are using their iPads more than when they first got the device, 30% are using it as their primary computer, they're spending as much time with it as they are their laptops, is Glucophage safe, and about equal numbers of people use the browser and apps to read news. Poynter's Damon Kiesow isn't reading much into the data Buy Glucophage No Prescription, , but he did find it surprising that about a third are reading news primarily on apps, considering how few news orgs have them out right now. That's good news for major media outlets, he said, though it doesn't mean much for the little guys.
Meanwhile, News Corp.'s James Murdoch said he thinks news apps for mobile devices like the iPad cannibalize newspaper sales, Glucophage forum, something Reuters' Felix Salmon wasn't sure about, and Poynter's Kiesow wasn't buying without seeing some data. News Corp., by the way, is reported to be close to launching its much-talked-about tablet news publication, and The Economist dropped its own iPad app this week.
Google News' crediting experiment: One cool little story worth highlighting: Google News announced it's introducing two tags for articles that will help indicate which articles were the first to report a story and which articles are essentially the same story on different sites. It's an experiment, as the Lab's Megan Garber noted, in finding out how willing news organizations are to give online credit where credit is due, Buy Glucophage No Prescription. As Search Engine Land's Matt McGee pointed out, ordering Glucophage online, they're based on the honor system, so there's nothing to stop spammers (or legit news organizations) from misusing the tags. CUNY j-prof C.W. Anderson wondered if the tags might provide some new research opportunities for scholars.
Reading roundup: Here's everything else worth taking a look at before you hit the weekend:
— Over at the National Sports Journalism Center, Jason Fry has written a wonderful column on the importance of the link to sports journalism, and it goes for all journalism as well. Buy Glucophage No Prescription, Elsewhere, Terry Heaton wrote about the value of the link in online advertising, a notion The Batavian's Howard Owens took issue with.
— A few paid-content tidbits: Connecticut's Valley Independent Sentinel is the latest local newspaper to make use of Journalism Online's Press+ paid-content system, The Times of London is partnering with a mobile broadband provider for a free-access offer at its website, and two new-media companies are working on an online news "EZ Pass."
— A couple pieces from last week I missed: Mashable's Vadim Lavrusik and Eastern Illinois j-prof Bryan Murley both urged j-schools to push some more boundaries in their teaching of news and technology.
— Weekly fuel for the pessimists among us: Poynter's Rick Edmonds on the signs that newspapers are still failing financially, and the nonprofit news site The Washington Independent announced it's closing up shop.
— And in the food-for-thought category: Jonathan Stray on the real value of social news, and CUNY j-prof C.W. Anderson at the Lab on journalism and online community. "We can’t will authentic community into being. It sort of sneaks up on us. And just as quickly — as soon as we turn our heads — it’s gone.".
Similar posts: Synthroid Cost. Lipitor No Rx. Purchase Retin A. Glucophage from canadian pharmacy. Where can i buy cheapest Flagyl online. Glucophage photos.
Trackbacks from: Buy Glucophage No Prescription. Buy Glucophage No Prescription. Buy Glucophage No Prescription. Is Glucophage safe. Glucophage coupon. Purchase Glucophage online no prescription.
[This review was originally posted at the Nieman Journalism Lab Cipro Cost, on Oct. 22, 2010.]
The value of hard news online: Perfect Market, a company that works on monetizing news online, released a study this week detailing the value of this summer's most valuable stories. The study included an interesting finding: The fluffy, celebrity-driven stories that generate so much traffic for news sites are actually less valuable to advertisers than relevant hard news. The key to this finding, purchase Cipro for sale, The New York Times reported, is that news stories that actually affect people are easier to sell contextual advertising around — and that kind of advertising is much more valuable than standard banner ads.
As Advertising Age pointed out, a lot of this goes back to keyword ads and particularly Google AdSense; a lot of, say, mortgage lenders and immigration lawyers are doing keyword advertising, Australia, uk, us, usa, and they want to advertise around subjects that deal with those issues. In other words, stories that actually mean something to readers are likely to mean something to advertisers too, Cipro Cost.
But the relationship isn't quite that simple, said GigaOM's Mathew Ingram. Advertisers don't just want to advertise on pages about serious subjects; they want to advertise on pages about serious subjects that are getting loads of pageviews — and you get those pageviews by also writing about the Lindsey Lohans of the world. SEOmoz' s Rand Fishkin had a few lingering questions about the study, and the Lab's Megan Garber took the study as a cue that news organizations need to work harder on "making their ads contextually relevant to their content."
The Times Co.'s paywall surprise: The New York Times Co. released its third-quarter earnings statement (your summary: print down, digital up, overall meh), and the Awl's Choire Sicha put together a telling graph that shows how The Times has scaled down its operation while maintaining at least a small profit, Cipro natural. Sicha also noted that digital advertising now accounts for a third of The Times' total revenue, which has to be an relatively encouraging sign for the company.
Times Co. Cipro Cost, CEO Janet Robinson talked briefly and vaguely about the company's paid-content efforts, led by The Times' own planned paywall and the Boston Globe's two-site plan. But what made a few headlines was the fact that the company's small Massachusetts paper, The Telegram & Gazette, actually saw its number of unique visitors increase after installing a paywall in August. Cheap Cipro, Peter Kafka of All Things Digital checked the numbers out with comScore and offered a few possible reasons for the bump (maybe a few Google- or Facebook-friendly stories, or a seasonal traffic boost).
The Next Web's Chad Catacchio pushed back against Kafka's amazement, pointing out that the website remains free to print subscribers, which, he says, probably make up the majority of the people interested in visiting the site of a fairly small community paper like that one. Catacchio called the Times Co.'s touting of the paper's numbers a tactic to counter the skepticism about The Times' paywall, order Cipro no prescription, when in reality, he said, "this is completely apples and oranges."
WikiLeaks vs. the world: The international leaking organization WikiLeaks has kept a relatively low profile since it dropped 92,000 pages of documents on the war in Afghanistan in July, but Spencer Ackerman wrote at Wired that WikiLeaks is getting ready to release as many as 400,000 pages of documents on the Iraq War as soon as next week, as two other Wired reporters looked at WikiLeaks' internal conflict and the ongoing "scheduled maintenance" of its site, Cipro Cost. WikiLeaks editor Julian Assange responded by blasting Wired via Twitter, and Wired issued a defense.
One of the primary criticisms of WikiLeaks after their Afghanistan release was that they were putting the lives of American informants and intelligence agents at risk by revealing some of their identities. Cipro online cod, But late last week, we found out about an August memo by Defense Secretary Robert Gates acknowledging that no U.S. intelligence sources were compromised by the July leak. Salon's Glenn Greenwald documented Cipro Cost, the numerous times government officials and others in the media asserted exactly the opposite.
Greenwald asserted that part of the reason for the government's rhetoric is its fear of damage that could be caused by WikiLeaks future leaks, and sure enough, it's already urging news organizations not to publish information from WikiLeaks' Iraq documents. At The Link, Nadim Kobeissi wrote an interesting account of the battle over WikiLeaks so far, Cipro alternatives, characterizing it as a struggle between the free, open ethos of the web and the highly structured, hierarchical nature of the U.S. government. "No nation has ever fought, or even imagined, a war with a nation that has no homeland and a people with no identity, Cipro from canadian pharmacy, " Kobeissi said.
Third-party plans at Yahoo and snafus at Facebook: An interesting development that didn't get a whole lot of press this week: The Wall Street Journal reported that Yahoo will soon launch Y Connect, a tool like Facebook Connect that will put widgets on sites across the web that allow users to log in and interact at the sites under their Yahoo ID. PaidContent's Joseph Tarkatoff noted that Y Connect's success will depend largely on who it can convince to participate (The Huffington Post is in so far), Cipro Cost.
The Wall Street Journal also reported another story about social media and third parties this week that got quite a bit more play, when it revealed that many of the most popular apps on Facebook are transmitting identifying information to advertisers without users' knowledge. Search Engine Land's Barry Schwartz found the juxtaposition of the two stories funny, and while the tech world was abuzz, Michael Arrington of TechCrunch gave the report the "Move on, real brand Cipro online, nothing to see here" treatment.
An unplanned jump from NPR to Fox News: Another week, another prominent member of the news media fired for foot-in-mouth remarks: NPR commentator Juan Williams lost his job for saying on Fox News' The O'Reilly Factor that he gets nervous when he sees Muslims in traditional dress on airplanes. Within 24 hours of being fired, though, Williams had a full-time gig (and a pay raise) at Fox News. Williams has gotten into hot water with NPR Cipro Cost, before for statements he's made on Fox News, which led some to conclude that this was more about Fox News than that particular statement.
NPR CEO Vivian Schiller explained why Williams was booted (he engaged in non-fact-based punditry and expressed views he wouldn't express on NPR as a journalist, she said), but, of course, not everybody was pleased with the decision or its rationale. (Here's Williams' own take on the situation.) Much of the discussion was pretty politically oriented — New York's Daily Intel has a pretty good summary of the various perspectives — but there were several who weren't pleased with the firing along media-related lines, Cipro pharmacy. The American Journalism Review's Rem Rieder said the move came too hastily, and The Atlantic's Jeffrey Goldberg said he doesn't like the trend of news organizations firing reporters over statements about Muslims or Jews.
Glenn Greenwald of Salon didn't care for this firing in particular, but said if you cheered the firings of those other reporters, you can't rail about this one for consistency's sake. The Columbia Journalism Review's Joel Meares, meanwhile, argued that Williams' firing sent the wrong message, especially for a news outlet known for taking advantage of controversial moments as opportunities for civil discourse: "Say something off-key, and you’re silenced, Cipro Cost. Expect that from CNN, After Cipro, but we thought better of NPR."
Newsweek and The Daily Beast's deal dies: With rumors swirling of a merger between Newsweek and the online aggregator The Daily Beast, we were all ready to start calling the magazine TinaWeek or NewsBeast last weekend. But by Tuesday, The Wall Street Journal had reported that the talks were off. There were some conflicting reports about who broke off talks; the Beast's Tina Brown said she got cold feet, but new Newsweek owner Sidney Harman said both parties backed off. (Turns out it was former GE exec Jack Welch, an adviser on the negotiations, where to buy Cipro, who threw ice water on the thing.)
Business Insider's Joe Pompeo gave word of continued staff shuffling, and Zeke Turner of The New York Observer reported on the frosty relations between Newsweek staffers and Harman, as well as their disappointment that Brown wouldn't be coming to "just blow it up." The Wrap's Dylan Stableford wondered what Newsweek's succession plan for the 92-year-old Harman is. Cipro Cost, If Newsweek does fall apart, Slate media critic Jack Shafer said, that wouldn't be good news for its chief competitor, Time.
Reading roundup: We've got several larger stories that would have been standalone items in a less busy week, so we'll start with those.
— As Gawker first reported, What is Cipro, The Huffington Post folded its year-old Investigative Fund into the Center for Public Integrity, the deans of nonprofit investigative journalism. As Gawker pointed out, a lot of the fund's problems likely stemmed from the fact that it was having trouble getting its nonprofit tax status because it was only able to supply stories to its own site. The Knight Foundation, which recently gave the fund $1.7 million, handed it an additional $250,000 to complete the merger, canada, mexico, india.
— Nielsen released a study on iPad users with several interesting findings, including that books, TV and movies are popular content on it compared with the iPhone and nearly half of tablet owners describe themselves as early adopters. Also in tablet news, News Corp. delayed its iPad news aggregation app plans, and publishers might be worried about selling ads on a smaller set of tablet screens than the iPad, Cipro Cost.
— From the so-depressing-but-we-can't-stop-watching department: The Tribune Co.'s woes continue to snowball, with innovation chief Lee Abrams resigning late last week and CEO Randy Michaels set to resign late this week. Abrams issued a lengthy self-defense, and Chicago Tribune columnist John Kass defended his paper, too.
— J-prof Jay Rosen proposed what he calls the "100 percent solution" — innovating in news trying to cover 100 percent of something. Paul Bradshaw liked the idea and began to build on it. Cipro Cost, — It's not a new debate at all, but it's an interesting rehashing nonetheless: Jeff Novich called Ground Report and citizen journalism useless tools that can never do what real journalism does. Megan Taylor and Spot.Us' David Cohn disagreed, strongly.
— Finally, former Los Angeles Times intern Michelle Minkoff wrote a great post about the data projects she worked on there and need to collaborate around news as data. As TBD's Steve Buttry wrote, "Each of the 5 W’s could just as easily be a field in a database. ... Databases give news content more lasting value, by providing context and relationships.".
Similar posts: Cipro For Sale. Cipro Dosage. Cipro Over The Counter. Cheap Zoloft. Generic Bactrim. Real brand Cipro online.
Trackbacks from: Cipro Cost. Cipro Cost. Cipro Cost. About Cipro. Cipro photos. Taking Cipro.